1. Home
  2. PRPL vs ATNM Comparison

PRPL vs ATNM Comparison

Compare PRPL & ATNM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Purple Innovation Inc.

PRPL

Purple Innovation Inc.

HOLD

Current Price

$8.94

Market Cap

34.1M

ML Signal

HOLD

Logo Actinium Pharmaceuticals Inc. (Delaware)

ATNM

Actinium Pharmaceuticals Inc. (Delaware)

HOLD

Current Price

$0.85

Market Cap

31.7M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
PRPL
ATNM
Founded
2010
2000
Country
United States
United States
Employees
N/A
N/A
Industry
Home Furnishings
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
34.1M
31.7M
IPO Year
2015
2013

Fundamental Metrics

Financial Performance
Metric
PRPL
ATNM
Price
$8.94
$0.85
Analyst Decision
Hold
Strong Buy
Analyst Count
2
2
Target Price
$0.65
$4.50
AVG Volume (30 Days)
173.0K
84.8K
Earning Date
04-28-2026
05-06-2026
Dividend Yield
N/A
N/A
EPS Growth
152.75
14.17
EPS
N/A
N/A
Revenue
$468,725,000.00
$90,000.00
Revenue This Year
$8.50
N/A
Revenue Next Year
$6.68
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
11.11
52 Week Low
$0.28
$0.81
52 Week High
$8.50
$1.81

Technical Indicators

Market Signals
Indicator
PRPL
ATNM
Relative Strength Index (RSI) 86.98 34.03
Support Level $0.54 $0.81
Resistance Level N/A $1.38
Average True Range (ATR) 0.62 0.03
MACD 0.40 -0.00
Stochastic Oscillator 98.58 24.61

Price Performance

Historical Comparison
PRPL
ATNM

About PRPL Purple Innovation Inc.

Purple Innovation Inc designs and manufactures sleep products. Using its GelFlex Grid technology, the company designs, manufactures, and offers branded comfort sleep products, including mattresses, pillows, cushions, mattress protectors, bases, sheets, and others. It markets and sells these products through direct-to-consumer e-commerce channels, retail brick-and-mortar wholesale partners, Purple showrooms, and third-party online retailers.

About ATNM Actinium Pharmaceuticals Inc. (Delaware)

Actinium Pharmaceuticals Inc is a biopharmaceutical company engaged in the development of targeted radiotherapies using its Antibody Radiation Conjugates (ARCs) platform, which combines monoclonal antibodies with radioisotopes to selectively target and destroy cancer cells. The company's product candidates include Iomab-B, an iodine-131 based radiotherapy for conditioning prior to hematopoietic stem cell transplantation, and Actimab-A, an actinium-225 based radiotherapy in clinical development for acute myeloid leukemia. The company is also advancing additional programs, including Iomab-ACT for cell and gene therapy conditioning and other preclinical candidates targeting solid tumors.

Share on Social Networks: